Taiwan Healthcare, Regulatory and Reimbursement Landscape - CountryFocus

Taiwan Healthcare, Regulatory and Reimbursement Landscape - CountryFocus

Summary

GlobalData, the industry analysis specialist, has released its latest report, “Taiwan Healthcare, Regulatory and Reimbursement Landscape - CountryFocus”. The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in the Taiwan. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of the Taiwan. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts.

Taiwan’s healthcare system is emerging as one of the most advanced healthcare systems in Asia, with government policies supporting the biomedical industry and digital health trends developing Taiwan as regional hub for pharma R&D at the intersection of technology and medical science. Taiwan’s pharmaceutical market increased from $2.41B in 2011 to $2.66B in 2018, at a Compound Annual Growth Rate (CAGR) of 1.42%. Taiwan’s medical devices market was valued at $2.25B in 2015, which increased at a CAGR of 3.3% to reach $2.56B in 2019. The pharmaceutical market growth is attributed to a rapidly aging population, an increase in non-communicable diseases, and a rise in medical tourism. A new drug price control mechanism to contain spending on healthcare is expected to limit pharmaceutical growth.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in the Taiwan, and includes -
- An overview of the pharmaceutical markets, comprising market size, segmentation, COVID-19 epidemiology and key drivers and barriers
- Profiles and SWOT analyses of the major players in the pharmaceutical market (Sinphar, China Chemical & Pharmaceutical Co, YungShin Global Holding Corp, TTY Biopharm Co, and Standard Chem & Pharm Co Ltd)
- Profiles and SWOT analyses of the major players in the medical device market (Fresenius, Medtronic, Stryker, Baxter, and TaiDoc)
- Detailed analysis about recent completed deals in the pharmaceutical and medical device market of Taiwan
- Information regarding the health-tech landscape of the country along with the major health-tech deals
- An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
- Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure
- An overview of the opportunities and challenges to growth in the Taiwan healthcare market

Reasons to Buy

This report will enhance your decision-making capability by allowing you to -
- Develop business strategies by understanding the trends shaping and driving the Taiwan healthcare market
- Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analysing the performance of various competitors
- Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership
- Identify, understand, and capitalize on the opportunities and challenges in the Taiwan healthcare market